Electroconvulsive therapy (ECT) is the most effective treatment for depression, yet its mechanism of action is unknown. Our goal was to investigate the neurobiological underpinnings of ECT response using longitudinally collected resting-state fMRI (rs-fMRI) in 16 patients with treatment-resistant depression and 10 healthy controls. Patients received bifrontal ECT 3 times a week under general anesthesia. We acquired rs-fMRI at three time points: at baseline, after the 1st ECT administration and after the course of the ECT treatment; depression was assessed with the Hamilton Depression Rating Scale (HAM-D). The primary measure derived from rs-fMRI was fractional amplitude of low frequency fluctuation (fALFF), which provides an unbiased voxel-wise estimation of brain activity. We also conducted seed-based functional connectivity analysis based on our primary findings. We compared treatment-related changes in HAM-D scores with pre- and post-treatment fALFF and connectivity measures. Subcallosal cingulate cortex (SCC) demonstrated higher BOLD signal fluctuations (fALFF) at baseline in depressed patients, and SCC fALFF decreased over the course of treatment. The baseline level of fALFF of SCC predicted response to ECT. In addition, connectivity of SCC with bilateral hippocampus, bilateral temporal pole, and ventromedial prefrontal cortex was significantly reduced over the course of treatment. These results suggest that the antidepressant effect of ECT may be mediated by downregulation of SCC activity and connectivity. SCC function may serve as an important biomarker of target engagement in the development of novel therapies for depression that is resistant to treatment with standard medications.

Translational Psychiatry (2016) 6, e789; doi:10.1038/tp.2016.54; published online 26 April 2016
ECT (or 2.5 weeks, given three ECT per week) and they were scanned for 
(Somatics, Lake Bluff, IL, USA) under general anesthesia. Ten out of sixteen 
ECT was performed with bifrontal placement on a Thymatron System IV 
MRI session (range: 4–6 HAM-D ratings 
the HAM-D before every ECT; remission was de 
within the prior 3 months.

Exclusion criteria were: (1) 
indicated (at least 2 failed adequate antidepressant trials in the past); (6) 
pretreatment score of at least 20 on the MADRS; (5) ECT was clinically 
associated networks more broadly, we utilized the top result from 
the fALFF analysis to define a seed for functional connectivity 
analysis. Since some prior studies have been confounded by 
heterogeneity with respect to timing of scans, we rigorously 
conducted scanning immediately before the first ECT treatment 
and within a 36-h window after the final ECT treatment. Unlike 
prior studies, we also included an intermediate scanning session 
after the first ECT treatment to account for acute effects of seizure 
and anesthesia on scanning parameters. We also examined 
healthy comparison subjects, to control for effects of time, as 
well as to determine if ECT-induced changes represented a 'normalization' of brain function in remitted patients.

MATERIALS AND METHODS

Participants and study design
Sixteen depressed patients (48.5 ± 13.6 years; six females) underwent rs-
fMRI at three TPs: before the first ECT session (TP1); within 36 h after 
the first ECT (TP2); and within 36 h after the last or eighth ECT, whichever 
occurred first (TP3) (Figure 1). Inclusion criteria for patients were: (1) 
between 18 and 70 years of age; (2) DSM-IV diagnosis of Major Depression, 
unipolar without psychotic features, or Bipolar I or Bipolar II Depression 
without psychotic features confirmed by SCID-IV interview; (3) pretreat 
ment-24-item Hamilton Rating Scale for Depression (HAM-D) score ≥ 21; (4) 
pretreatment score of at least 20 on the MADRS; (5) ECT was clinically 
indicated (at least 2 failed adequate antidepressant trials in the past); (6) 
competency to provide informed consent. Exclusion criteria were: (1) 
current diagnosis of delirium, dementia or amnestic disorder; (2) diagnosis 
of mental retardation; (3) baseline Mini Mental State Exam (MMSE) 
score < 21, or a total score falling 2 s.d. below the age- and education-
adjusted mean (whichever is less); (4) any active general medical condition 
or CNS disease, which can affect cognition or response to treatment; (5) 
current (within the past 3 months) diagnosis of active substance 
dependence, or active substance abuse within the past week; (6) ECT 
within the prior 3 months.

During the course of the study, patients’ symptoms were assessed with 
the HAM-D before every ECT; remission was defined as two consecutive 
HAM-D ratings ≤ 10. Patients received on average 6.4 ECT before their final 
MRI session (range: 4–8). Ten patients reached remission before the eighth 
ECT (or 2.5 weeks, given three ECT per week) and they were scanned for 
the third time after the last ECT session, when they fulfilled remission 
criteria. Fourteen of the patients had > 50% reduction in HAM-D at TP3. 
ECT was performed with bifrontal placement on a Thymatron System IV 
(Somatics, Lake Bluff, IL, USA) under general anesthesia. Ten out of sixteen 
patients received methohexital 1 mg kg\(^{-1}\) as an inducing agent. We conducted post hoc analyses, indicating no significant effect of anesthesia type on our results 
(see Supplementary Material). All patients received succinylcholine 
1 mg kg\(^{-1}\) as a muscle relaxant. Patients received ECT 3 times a week 
using 150% of seizure threshold energy. All patients started ECT treatment 
as inpatients and their psychotropic medications were discontinued. The only psychotropic medication allowed during the study was lorazepam up 
to 3 mg per day for anxiety or insomnia. 
Ten healthy age-matched volunteers (45.6 ± 13.1 years; five females) were 
recruited to serve as a control population for the imaging measures. The 
controls underwent the same imaging protocol with similar TPs as the patients.

Written informed consent was obtained from all participants in 
accordance with the guidance of the North Shore—LIJ Health System 
Institutional Review Board, which approved this study. 

Demographic details of patients and controls are listed in 
Supplementary Table S1 in the Supplement.

MRI protocol

Image processing 
We used script libraries derived from the 1000 Functional Connectomes Project (http://www.nitrc.org/projects/fcon_1000;4 these libraries, based in FSL (http://www.fmrib.ox.ac.uk) and AFNI (http://afni.nimh.nih.gov/afni), were used for preprocessing along with a lab-developed script in the R 
statistical language (Vienna, Austria) for additional analysis as described 
below. Standard preprocessing and motion analysis steps are detailed in 
the Supplement.

Image analysis 
Image analysis was carried out in two steps: voxel-wise fALFF and seed-based 
connectivity analysis. In the analysis, we calculated these measures independently 
in the four 5-min rs-fMRI runs (no concatenation) and used them as intra-subject repetitions in the following higher order statistical 
tests. First, fALFF images were calculated in each run. In this process, 
utilizing Fourier Transformation of the unfiltered signal in every voxel, we 
calculated the power of BOLD signal in the low frequency range of 
0.01–0.08 Hz and divided it by the power of BOLD signal across the entire 
frequency range (0–0.25 Hz); this approach has proved to be an effective 
way to correct for non-physiological noise in the BOLD signal.\(^{21}\) 
Z-normalized fALFF maps were assessed with voxel-wise statistical 
parametric mapping (SPM5, London, UK; family-wise error-corrected 
P < 0.05); for our primary analysis, we compared baseline (TP1) with 
the third time point (TP3). We implemented repeated measures of ANOVA with 
a flexible factorial model, with three factors: subjects (independent across 
levels), TPs and runs (dependent across levels), and tested TP1 > TP3 and 
TP1 < TP3 with appropriate contrast over the main effect time. We applied 
a conservative threshold for statistical significance, reporting clusters 
where at least 10 voxels survived family-wise error correction at P < 0.05 
level. As a follow-up exploratory analysis, to more broadly examine 
treatment-relevant networks, we also report clusters meeting an uncor 
corrected P < 0.001.

Next, we conducted seed-based correlation analysis derived from 
the most significant voxels identified from the fALFF analysis. Specifically, we 
used 3 × 3 × 3 voxel size box around the peak coordinates of the findings 
of the voxel-based analysis (fALFF). Individual seed-based correlation maps 
were created and Fisher transformed, followed by SPM5 voxel-based 
analysis, utilizing the strict statistical threshold of false discovery rate 
corrected P < 0.05 with minimum 10 voxels.

In follow-up post hoc analyses, we repeated both fALFF and seed-based 
connectivity analyses including all the three TPs from both patients and 
healthy controls. To simplify interpretation and display of data, the four 
runs were averaged during these analyses in the result.
RESULTS
Patients’ mood improved significantly with ECT treatment from TP1 to TP3 (HAM-D decrease: 17.9 ± 5.1, t = 9.1, degree of freedom (df) = 30, P < 0.001, HAM-D % change: 63.9 ± 16.6%; mean HAM-D at baseline: 28.2, at TP2: 21.6, at TP3: 10.3).

Whole brain voxel-wise analysis revealed a significant change in fALFF from pre- to post-treatment TPs in the subcallosal cingulate cortex (SCC) (Figure 2a). Post hoc analysis of SCC across both groups (patients and controls) and all three TPs revealed that fALFF was significantly higher at baseline in depressed patients compared with HC (t = 3.43, df: 21.4, P = 0.002; Figure 3a). Note that the HC value (blue color in Figure 2b) did not change across the 3 TPs (F_{1,25} = 0.002, P = 0.97). During the course of ECT, patients’ fALFF not only decreased, but compared with control data, it was normalized; at TP3 the difference between HC and MDD patients was non-significant (t = 0.38, df: 15.4, P = 0.7). The elevated baseline fALFF in SCC significantly correlated with response (r = 0.52, t = 2.25, df: 14, P = 0.04), the higher baseline value predicted better response. The fALFF decrease from TP1 to TP3 had a trend level correlation with clinical improvement (r = 0.51, P = 0.08, t = 1.94, df = 11).

Using the exploratory threshold of the primary TP3 versus TP1 analysis, fALFF of other key fronto-limbic regions implicated previously in depression25 (bilateral insula, anterior cingulate, dorsolateral prefrontal cortex and hippocampus) were also decreased (Table 1a, Supplementary Figure S1). No regions were found which increased fALFF during the course of ECT treatment, even at this lower threshold. Post hoc analyses of these additional regions across all TPs and subjects are in the Supplementary Figure S2 in the Supplement. Most of these regions demonstrated a pattern of change over time that was similar to the SCC, with the majority of the reduction observed between TP2 and TP3. However, it is notable that the hippocampus demonstrated all of the reduction (on average) between TP1 and TP2, indicating that fALFF changes in that structure may be a result of seizure and/or anesthesia. In addition, it should be noted that the dorsolateral prefrontal cortex fALFF values began in the normal range and then were driven far below that range after ECT.

We used the SCC cluster (the most significant region of the fALFF analysis) as a seed region and generated individual correlation maps (Supplementary Figure S3 in the Supplement). The comparison of these maps between TP1 and TP3 revealed significant decrease in the correlation between SCC and three regions—vmPFC, bilateral parahippocampal gyrus and bilateral temporal pole. We also detected increased correlations in the right supramarginal gyrus (Table 1b, Figure 3). The post hoc analysis revealed that in regions where we measured decreased correlations between TP1 and TP3, the correlation values were originally positive (P < 0.001, one sample t-test on Fisher transformed values) and in the case of vmPFC and hippocampus values were higher than normal (P < 0.001, t = −3.8, df = 23.5 and P = 0.048, t = −2.08, df = 22.9, respectively). These numbers were trending down to zero in the hippocampus and in the temporal pole (Figure 3). In the case of vmPFC it was normalized (higher than normal at baseline (r = 0.4) which trended to normal values (r = 0.2) (Figure 3). By contrast, post hoc analysis in the supramarginal cortex revealed that correlations were significantly negative at baseline (P < 0.001, one sample t-test) and increase in these values meant decreasing correlation in absolute value. Therefore all four of these regions had weaker relationships with SCC at the end of treatment. Notably, none of the connectivity changes in this analysis correlated with clinical response and none of the baseline connectivity values predicted response.

DISCUSSION
We found that the SCC demonstrated higher BOLD signal fluctuations at baseline in depressed patients and fALFF decreased over the course of treatment (Figure 2). These data are consistent with previous findings implicating the central role of the SCC in the pathophysiology of depression and its treatment. Previous studies of the pharmacologic and psychotherapeutic treatment of depression have provided converging evidence that depressed patients display higher SCC activity at baseline, and that reduction in SCC activity corresponds with clinical improvement.26–33 Similarly, catecholamine depletion causes increased activity in the SCC, in correlation with increasing severity of depressive symptoms.34 Notably, these prior studies utilized PET or SPECT technologies. To our knowledge, the present study is the first report demonstrating regionally specific SCC effects of treatment.

Figure 2. Decreases in fALFF between TP1 to TP3. (a) Voxel-based statistics across whole brain. (b) Post hoc analysis of the primary result including all the three time points from both patients and healthy controls (with blue). These results show that fALFF was higher at baseline in depressed patients, and it was normalized during the course of ECT (see statistics in the text). ECT, electroconvulsive therapy; fALFF, fractional amplitude of low frequency fluctuation; TP, time point.
Table 1. fALFF and seed-based imaging analysis results

| Regions                     | Peak MNI coordinates | Peak t-value | Cluster size (t > 5.1) FWE, P < 0.05 | Cluster size (t > 3.1) uncorr., P < 0.001 |
|-----------------------------|----------------------|--------------|--------------------------------------|------------------------------------------|
| (a) fALFF decrease during the course of ECT |                       |              |                                      |                                          |
| Subcallosal cingulate cortex | 8, 26, −6            | 6.81         | 32                                   | 271                                       |
| Right cerebellum            | 42, −62, −32         | 5.84         | 9                                    | 173                                       |
| Right hippocampus           | 26, −6, −30          | 5.46         | 3                                    | 145                                       |
| Left DLPFC                  | −34, 34, 30          | 5.37         | 3                                    | 136                                       |
| Right Insula                | 46, 0, 2             | 5.28         | 1                                    | 129                                       |
| Left Insula                 | −38, −16, −6         | 5.13         | 1                                    | 610                                       |
| Anterior cingulate cortex   | 6,8,22               | 5.12         | 1                                    | 187                                       |

| Regions                     | Peak MNI coordinates | Peak t-value | Cluster size (voxels) P < 0.05 FDR and cluster size > 100 | Direction of change |
|-----------------------------|----------------------|--------------|-------------------------------------------------------------|---------------------|
| (b) Regions with altered SCC correlations |                       |              |                                                             |                     |
| Ventromedial prefrontal cortex | −2, 52, −10          | 4.93         | 415                                                         | ↓                   |
| Left parahippocampal gyrus  | −34, −32, −26        | 5.03         | 428                                                         | ↓                   |
| Right parahippocampal gyrus | 30, −28, −24         | 5.28         | 168                                                         | ↓                   |
| Left temporal pole          | −60, 8, −6           | 5.82         | 387                                                         | ↓                   |
| Right temporal pole         | 44,10, −18           | 4.93         | 563                                                         | ↓                   |
| Right supramarginal cortex  | 46, −44, 14          | 4.85         | 129                                                         | ↑                   |

Abbreviations: ECT, electroconvulsive therapy; DLPFC, dorsolateral prefrontal cortex; fALFF, fractional amplitude of low frequency fluctuation; FDR, false discovery rate; FWE, family-wise error; SCC, subcallosal cingulate cortex.
with ECT, and is also the first to demonstrate that fALFF analysis of rs-fMRI data can yield these results.

Furthermore, higher baseline SCC fALFF values predicted better clinical response to ECT treatment, which if replicated could lead to an MRI-based prognostic biomarker. Interestingly, SCC hyperactivation has consistently predicted poor response with other treatment modalities and was consistently reported as elevated in TRD.29,32 This inverse correlation between SCC and response to conventional treatments implies that most forms of treatment cannot consistently modify the activity in this area. Speculatively, it is possible that any intervention which reliably decreases SCC activity would have clinical efficacy in TRD. Indeed, direct deactivation of the SCC is not only possible through deep brain stimulation (DBS), but was shown effective in a subset of severely treatment-resistant population.38,39 Similarly, our results suggest that ECT is able to decrease SCC activity as well. This is an excellent example how target identification of a mechanism of action or a neuronal node in a neuropsychiatric disorder can help to develop novel therapies.8 We are aware of the negative outcomes of the recently conducted SCC-targeted DBS clinical studies. Based on this study it can be speculated that a clinical DBS or ECT study on preselected patients with high baseline SCC activity would be more likely to yield positive results. In addition, ECT may be more effective for decreasing SCC activity due to its more global stimulation compared with the current spatial limitations of DBS targeting.

It is notable that hippocampus was the most sensitive to seizure as indicated by its dramatic reduction in fALFF from TP1 to TP2 (Supplementary Figure S2). This observation is consistent with the notion that the hippocampus is one of the most seizure sensitive parts of the human brain, giving it a central role in seizure therapies. An alternative explanation is also possible; since the HAM-D values decreased significantly between TP1 and TP2 (28.2–21.6), the hippocampal changes may reflect mood-related improvements. Indeed in a recent study hippocampal volume was shown to correlate with overall ECT-related clinical response.37

The strong modulation of fALFF values in the SCC is not necessarily the direct effect of ECT, but could be an indirect effect mediated through other regions of the emotion regulation network. To explore this question, we conducted a seed-based analysis to measure functional correlations from the SCC. vmPFC, bilateral parahippocampal gyrus and bilateral temporal pole decreased their connectivity with SCC while right supramarginal gyrus connectivity increased significantly between TP1 and TP3 (Table 1b, Figure 3). It is intriguing that vmPFC, bilateral parahippocampal gyrus and bilateral temporal lobe have strong bidirectional neuroanatomic connectivity with SCC.38 Post hoc analysis revealed that all of these changes in connectivity were in the direction of loss of relationship, meaning that correlation was getting closer to zero after ECT. These results fit very well with previous observations found in depression and ECT treatment; previous findings have indicated that depression is a ‘hyperconnectivity’ syndrome, with increased connectivity among key regions implicated in mood regulation.39 In addition, recent rs-fMRI studies with ECT treatment40–42 found that connectivity decreased,40 or the anti-correlation diminished41 between key midline frontal regions such as ACC and SCC and other key cognitive control areas like DLPCF. Leaver et al.43 also reported normalization of dysconnectivity between ventral striatum and ventral default mode network. In our results two of these connectivities, bilateral parahippocampal gyrus and vmPFC, were hyperconnectivities at baseline and connectivity normalized on treatment. These regions are implicated in emotional regulation and appraisal44,45 and thought to be primarily responsible for automatic regulation of emotion, in contrast to regions more dorsal and lateral in frontal regions, which are involved in voluntary regulation.46 Furthermore these regions are part of the default mode network. Hyperactivity of this network is thought to intensify self-referential thoughts and make patients unable to terminate rumination, thereby prohibiting availability of resources for voluntary control of emotions. The third region, bilateral temporal pole, is less frequently discussed in the literature, but an increasing amount of evidence indicates its key role in emotional and social processing (for review see the study by Olson et al.47).

The exact meaning of fALFF and its relation to the corresponding connectivity measures is not fully understood. In principal, these measures should be independent. In a recent study, however, healthy controls showed strong region-specific correlation between ALFF and voxel-based connectivity strength in the cingulate cortex, superior temporal cortex, insula, medial frontal cortex, parahippocampal cortex and basal ganglia.48 This means that our results suggest either that the altered regional neurophysiology results in lower ALFF and altered connectivity, or that altered incoming connectivities influence the local low frequency fluctuations. The present study is limited in its ability to disentangle these two mechanisms.

We acknowledge several additional limitations in this study. First, the lack of correlation between clinical measures and changes in connectivity can be due to the low sample size. Second, the use of ketamine as an anesthetic agent in six of our cases is a potential confound. Importantly, we reanalyzed our data in the methohexital-only subpopulation, and observed the same results (Supplementary Figure S4 in the Supplementary Materials), suggesting that our findings are not driven by use of ketamine as an anesthetic agent in a subset of patients. In addition, while a strength of our study was the uniformity of electrode placement (bifrontal), our ability to generalize the results to other types of ECT electrode placements is limited. Further studies with the more common unilateral placement are required.

In summary, the present study provides evidence that SCC and its correlated regions (vmPFC, parahippocampal gyrus and temporal lobe) are central in the mechanism of action of the bifrontal ECT. We showed here that fALFF could be used as a sensitive marker of SCC activity, which not only correlates with mood states, but also predicts response to ECT. In contrast to other treatment modalities, hyper-activated SCC seems to be a potential therapeutic target for ECT treatment.

CONFLICT OF INTEREST

The collection of this data was supported by grants U01MH066123 from National Institute of Mental Health and NARSAD grant 17579 from Brain and Behavior Research Foundation. AKM is a consultant to Genomind and Forum Pharmaceuticals. This support is unrelated to the manuscript. The remaining authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank the ECT team at the Zucker Hillside Hospital and the patients and healthy comparison subjects who volunteered for the study.

REFERENCES

1 Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.
2 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–1917.
3 Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Br J Psychiatry 2002; 181: 284–294.
4 UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361: 799–808.
5 Fink M, Taylor MA. Electroconvulsive therapy: evidence and challenges. JAMA 2007; 298: 330–332.
6 Grover S, Mattoo SK, Gupta N. Theories on mechanism of action of electroconvulsive therapy. Ger J Psychiatry 2005; 8: 70–84.
7 Kellner CH, Greenberg RM, Murrough JW, Bryson EQ, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. Am J Psychiatry 2012; 169: 1238–1244.
8 Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET et al. Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev 2013; 37: 2438–2444.
9 Zhuo C, Yu C. Functional neuroimaging changes subsequent to electroconvulsive therapy in unipolar depression: a review of the literature. J ECT 2014; 30: 265–274.
10 Volkow ND, Bellar S, Mullanli N, Jould L, Dewey S. Effects of electroconvulsive therapy on brain glucose metabolism: a preliminary study. Convuls Ther 1988; 4: 199–205.
11 Henry ME, Schmidt ME, Matochik JA, Stoddard EP, Potter WZ. The effects of ECT therapy in unipolar depression: a review of the literature. J ECT 2001; 17: 33–40.
12 Nobler MS, Sackeim HA, Prohovnik I, Moeller JR, Mukherjee S, Schnur DB et al. Regional cerebral blood flow in mood disorders, III. Treatment and clinical response. Arch Gen Psychiatry 1994; 51: 884–897.
13 Norber M, Oquendo MA, Kegeles LS, Malone KM, Campbell CC, Sackeim HA et al. Decreased regional brain metabolism after ecm. Am J Psychiatry 2001; 158: 305–308.
14 Schmidt EJ, Reininghaus EZ, Enzinger C, Ebner C, Hofmann P, Kaphammer HP. Changes in brain metabolism after ECT-potential erosion tomography in the assessment of changes in glucose metabolism subsequent to electroconvulsive therapy—lessons, limitations and future applications. J Affect Disord 2006; 106: 203–208.
15 Suwa T, Namiki C, Takaya S, Oshita A, Ishizu K, Fukuda H et al. Corticolimbic balance shift of regional glucose metabolism in depressed patients treated with ECT. J Affect Disord 2012; 136: 1039–1046.
16 Yuuki N, Ida I, Oshima A, Kumano H, Takahashi K, Fukuda M et al. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. Acta Psychiatr Scand 2005; 112: 257–265.
17 Yatham LN, Clark CC, Zis AP. A preliminary study of the effects of electroconvulsive therapy on regional brain glucose metabolism in patients with major depression. J ECT 2007; 23: 265–273.
18 McCormick LM, Boles Ponto LL, Pierson RK, Johnson HJ, Magnotta V, Brum MCM. Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy. J ECT 2007; 23: 265–273.
19 Reininghaus EZ, Reininghaus B, Ille R, Fitz W, Lassnig E-M, Ebner C et al. Clinical effects of electroconvulsive therapy in severe depression and concomitant changes in cerebral glucose metabolism—an exploratory study. J Affect Disord 2013; 146: 290–294.
20 Abbott CC, Gallegos P, Rediske N, Lemske NT, Quinn DK. A review of longitudinal electroconvulsive therapy: neuroimaging investigations. J Genint Psychiatry Neuro 2014; 27: 33–46.
21 Zou Q-H, Zhu C-Z, Yang Y, Zuo X-N, Long Y-X, Yao O-J et al. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF. J Neurosci Methods 2008; 172: 137–141.
22 Aiello M, Salvatore E, Cachia A, Pappatà S, Cavalleri C, Prinster A et al. Relationship between simultaneously acquired resting-state regional cerebral glucose metabolism and functional mri: a pET/mr hybrid scanner study. NeuroImage 2015; 111: 111–121.
23 Nugent AC, Martinez A, D’Alfonso A, Zarate CA, Theodore WH. The relationship between glucose metabolism, resting-state fMRI BOLD signal, and GABA-A binding potential: a preliminary study in healthy subjects and those with temporal lobe epilepsy. J Cereb Blood Flow Metab 2015; 35: 583–591.
24 Biswal BB, Mennes M, Zuo X-N, Gohel S, Kelly C, Smith SM et al. Toward discovery of science of human brain function. Proc Natl Acad Sci USA 2010; 107: 4734–4739.
25 Pizzagalli DA. Fronto-cingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011; 36: 183–206.
26 Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci Off J Soc Neurosci 1992; 12: 3628–3641.
27 Wu J, Buchbaum MS, Gillin JC, Tang C, Cadwell S, Wieand M et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 1999; 156: 1149–1158.
28 Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48: 830–843.
29 Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651–660.
30 Dunn RT, Kimbell TA, Ketter TA, Faye MA, Willis MW, Luckenbaugh DA et al. Principal components of the beck depression inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry 2002; 51: 387–399.
31 Bauer M, London ED, Rasgon N, Berman SM, Faye MA, Altschuler LL et al. Supra-physiological doses of levomethoxyine alter regional cerebral metabolism and improvement in bipolar disorder. Mol Psychiatry 2005; 10: 455–469.
32 Kumanu H, Ida I, Oshima A, Takahashi K, Yuuki N, Amanuma M et al. Brain metabolic changes associated with predisposition to onset of major depressive disorder and adjustment disorder in cancer patients – A preliminary PET study. J Psychiatr Res 2007; 41: 591–599.
33 Inagaki M, Yoshikawa E, Kobayakawa M, Matsuoka Y, Sugawara Y, Nakano T et al. Regional cerebral glucose metabolism in patients with secondary depressive episodes after fatal pancreatic cancer diagnosis. J Affect Disord 2007; 99: 231–236.
34 Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M et al. Neural response to cathecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 2008; 65: 521–531.
35 Konarski JZ, Kennedy SH, Segal ZV, Lau MA, Bieling PJ, McIntyre RS et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci JPN 2009; 34: 175–180.
36 Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64: 461–467.
37 Jönsson Espinosa RT, Pirnia T, Shi J, Wang Y, Ayers B et al. Structural plasticity of the hippocampus and amygdala induced by electroconvulsive therapy in major depression. Biol Psychiatry 2016; 79: 282–292.
38 Hamani C, Mayberg H, Stone S, Laxton A, Haber S, Lozano AM. The subcallosal cingulate gyrus in the context of major depression. Biol Psychiatry 2011; 69: 301–308.
39 Sheline YJ, Price JL, Yan Z, Mintun MA. Resting-state functional mri in depression unmarks increased connectivity between networks via the dorsal nsa. Proc Natl Acad Sci USA 2010; 107: 11020–11025.
40 Perrin JS, Merz S, Bennett DM, Currie J, Steele DJ, Reid IC et al. Electroconvulsive therapy reduces frontal cortical connectivity in severe depressive disorder. Proc Natl Acad Sci USA 2012; 109: 5464–5468.
41 Abbott CC, Lemke NT, Gopal S, Thoma RJ, Bustillo J, Calhoun VD et al. Electroconvulsive therapy response in major depressive disorder: a pilot functional network connectivity resting state fMRI investigation. Front Psychiatry 2013; 4: 10.
42 Abbott CC, Jones T, Lemke NT, Gallegos P, McClintock SM, Mayer AR et al. Hippocampal structural and functional changes associated with electroconvulsive therapy response. Transl Psychiatry 2014; 4:e483.
43 Leaver AM, Espinoza R, Joshi SH, Vasavada M, Nijau S, Woods RP et al. Desynchronization and plasticity of striato-frontal connectivity in major depressive disorder. Cereb Cortex 2015; pii: bnv207.
44 Phillips M, Ladouceur C, Drevets W. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol Psychiatry 2008; 13: 829–857.
45 Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 2003; 54: 515–528.
46 Rive MM, van Rooijen G, Veltman DJ, Phillips ML, Schene AH, Ruhé HG. Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. Neurosci Biobehav Rev 2013; 37: 2529–2533.
47 Olson IR, Plotzker A, Ezzyat Y. The Enigmatic temporal pole: a review of material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/